A federal court blocked a widely used abortion pill from distribution by mail. Here’s what to know
A panel of the 5th U.S. Circuit Court of Appeals ruled that the abortion pill mifepristone must be distributed in person, a decision expected to be appealed to the Supreme Court
A federal appeals court has issued a ruling that restricts access to mifepristone, one of the most widely used methods for abortion in the United States. A panel of the New Orleans-based 5th U.S. Circuit Court of Appeals determined that the medication can no longer be distributed by mail and must instead be provided to patients in person at clinics. This restriction applies across all 50 states, affecting even those regions where abortion remains legal and unrestricted.[1][2]
The decision comes at a time when mail-order prescriptions have become a critical avenue for abortion access following the 2022 Supreme Court ruling that overturned Roe v. Wade. Since that landmark decision allowed for the enforcement of various state-level bans, the ability to receive medication by mail has served as a primary way for individuals to obtain abortions, including those residing in states with strict prohibitions.[1][2]
Friday's ruling is currently in effect as the litigation proceeds through the federal court system. Legal experts and observers expect the case to be appealed to the U.S. Supreme Court for a final determination. In the interim, the requirement for in-person distribution significantly limits the reach of medication abortion, which has grown in prevalence over the last several years.[1][2]
